About This Fund
Alta Life Sciences Spain I FCR is a Spanish venture capital fund managed by AltamarCAM Partners focused on multi-stage financing of life sciences companies in Spain. The fund invests across biotechnology, biopharmaceuticals, medical devices, diagnostics, genomics, and digital health, from seed through late-stage rounds. It takes direct equity stakes alongside management teams and positions itself as a bridge between Spain's scientific ecosystem and international venture capital expertise. Registered with the CNMV (registration no. 203, ISIN ES0108631005), the fund had its first close in September 2016 and reached its final close in December 2019 at €79 million in total committed capital. The fund holds 9 portfolio companies and achieved a notable exit with Sanifit, acquired by Vifor Pharma for up to €375 million. As of October 2025, the fund is co-managed by Asabys Partners following the integration of AltamarCAM's Aliath Bioventures life sciences team into Asabys. The successor vehicle is ACP Aliath Bioventures II FCR. AltamarCAM Partners' main business is fund-of-funds and secondaries in private markets, making Alta Life Sciences Spain I FCR a direct VC carve-out within the broader platform.